The study reveals a strong association between gut microbial carbohydrate metabolism and insulin resistance, pointing to gut microbes as a key player in metabolic syndrome and type 2 diabetes. Targeting these microbial activities could offer a new therapeutic pathway for improving insulin resistance and overall metabolic health.
Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update – Biotech Investments
Issuer: Immunic AG / Key word(s): Miscellaneous 31.10.2024 / 11:30 CET/CEST The issuer is solely responsible for the content of this announcement. Immunic, Inc. to